MX338940B - Identificacion de epitopos ige novedosos. - Google Patents
Identificacion de epitopos ige novedosos.Info
- Publication number
- MX338940B MX338940B MX2011007343A MX2011007343A MX338940B MX 338940 B MX338940 B MX 338940B MX 2011007343 A MX2011007343 A MX 2011007343A MX 2011007343 A MX2011007343 A MX 2011007343A MX 338940 B MX338940 B MX 338940B
- Authority
- MX
- Mexico
- Prior art keywords
- ige
- subject
- high affinity
- identification
- novel
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a un anticuerpo aislado o un fragmento que se une al antígeno del mismo, que comprende una región variable de cadena liviana que comprende CDRL1, CDRL2 y CDRL3 y una región variable de cadena pesada que comprende CDRH1, CDRH2 y CDRH3, en donde CDRL1consiste de la SEQ ID NO: 5, CDRL2 consiste de la SEQ ID NO: 6, CDRL3 consiste de la SEQ ID NO: 78, CDRH1 consiste de la SEQ ID NO: 15, CDRH2 consiste de la SEQ ID NO: 25 y CDRH3 consiste de la SEQ ID NO: 26, en donde el anticuerpo se une específicamente a IgE.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44422903P | 2003-02-01 | 2003-02-01 | |
| PCT/US2004/002894 WO2004070011A2 (en) | 2003-02-01 | 2004-02-02 | HIGH AFFINITY ANTI-HUMAN IgE ANTIBODIES |
| PCT/US2004/002892 WO2004070010A2 (en) | 2003-02-01 | 2004-02-02 | A method for generating high affinity antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX338940B true MX338940B (es) | 2016-05-06 |
Family
ID=32850839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011007343A MX338940B (es) | 2003-02-01 | 2004-07-29 | Identificacion de epitopos ige novedosos. |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US7531169B2 (es) |
| EP (4) | EP1592776A4 (es) |
| JP (4) | JP4764334B2 (es) |
| CN (3) | CN1829806A (es) |
| AU (3) | AU2004209637A1 (es) |
| CA (2) | CA2514840C (es) |
| CY (2) | CY1118063T1 (es) |
| DK (2) | DK2407485T3 (es) |
| ES (2) | ES2566778T3 (es) |
| HK (3) | HK1085771A1 (es) |
| HU (2) | HUE028458T2 (es) |
| IL (1) | IL176940A (es) |
| MX (1) | MX338940B (es) |
| PT (1) | PT2000481E (es) |
| SI (2) | SI2000481T1 (es) |
| WO (2) | WO2004070010A2 (es) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| US20060234296A1 (en) * | 2003-02-01 | 2006-10-19 | Sanjaya Singh | Method for generating high affinity antibodies |
| ES2566778T3 (es) * | 2003-02-01 | 2016-04-15 | Tanox, Inc. | Anticuerpos anti-IgE de humano de alta afinidad |
| JP4943161B2 (ja) | 2003-12-23 | 2012-05-30 | ジェネンテック， インコーポレイテッド | 新規抗ｉｌ１３モノクローナル抗体での癌の処置 |
| SG183683A1 (en) * | 2004-02-02 | 2012-09-27 | Tanox Inc | Identification of novel ige epitopes |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| WO2006055704A2 (en) * | 2004-11-17 | 2006-05-26 | Curagen Corporation | Antibodies directed to ten-m proteins and uses thereof |
| AU2006297304B2 (en) * | 2005-09-29 | 2012-05-17 | Medimmune, Llc | Method of identifying membrane LG specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells |
| AR065368A1 (es) | 2007-02-15 | 2009-06-03 | Astrazeneca Ab | Anticuerpos para moleculas de ige |
| SI2132230T1 (sl) | 2007-03-22 | 2014-07-31 | Genentech, Inc. | Apoptotska protitelesa, ki veĹľejo membransko-vezan IgE |
| DE102007052281A1 (de) * | 2007-11-02 | 2009-05-07 | Zenteris Gmbh | Einschritt-Multiplex-Immuntest |
| US20100248971A1 (en) | 2007-12-03 | 2010-09-30 | Takashi Inagaki | Process for antibody production |
| US20130338038A1 (en) | 2007-12-21 | 2013-12-19 | Pdl Biopharma, Inc. | Method of screening complex protein libraries to identify altered properties |
| CN101230103B (zh) * | 2008-03-25 | 2011-09-07 | 中国医药集团总公司四川抗菌素工业研究所 | 一全人源重组抗-IgE抗体 |
| EP2853545B8 (en) | 2008-09-17 | 2023-04-05 | Xencor, Inc. | Antibody specific for IgE |
| US9187568B2 (en) | 2009-05-07 | 2015-11-17 | Stallergenes S.A. | Use of IgG1 immunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and manifestations via the mucosal route |
| EP2494356B1 (en) | 2009-10-26 | 2017-03-15 | Genentech, Inc. | Assays for detecting antibodies specific to therapeutic anti-ige antibodies and their use in anaphylaxis |
| JP2013523153A (ja) * | 2010-04-07 | 2013-06-17 | アッヴィ・インコーポレイテッド | ＴＮＦ−α結合タンパク質 |
| AR089434A1 (es) | 2011-12-23 | 2014-08-20 | Genentech Inc | Procedimiento para preparar formulaciones con alta concentracion de proteinas |
| WO2013116287A1 (en) | 2012-01-31 | 2013-08-08 | Genentech, Inc. | Anti-ig-e m1' antibodies and methods using same |
| BR112014028600B1 (pt) | 2012-05-18 | 2022-11-22 | Genentech, Inc | Formulações de suspensão compreendendo anticorpo monoclonal de alta concentração, seu método de preparação, seu uso e dispositivo para sua administração subcutânea, e método para produção de um artigo de fabricação |
| ES2900342T3 (es) | 2012-08-21 | 2022-03-16 | Sanofi Biotechnology | Métodos para tratar o prevenir el asma administrando un antagonista de IL-4R |
| TWI633891B (zh) | 2013-06-04 | 2018-09-01 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法 |
| TWI682781B (zh) | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| US10196458B2 (en) | 2013-07-26 | 2019-02-05 | The Regents Of The University Of California | Anti-immunoglobulin E antibodies and methods of using thereof |
| CN106471372B (zh) | 2014-01-29 | 2019-10-11 | 通用电气健康护理生物科学股份公司 | 用于相互作用分析的方法和系统 |
| CN106062000B (zh) | 2014-02-28 | 2021-05-28 | 瑞泽恩制药公司 | 通过施用il-4r拮抗剂治疗皮肤感染的方法 |
| CA2943588C (en) * | 2014-06-17 | 2019-04-30 | Academia Sinica | Humanized anti-ige antibodies that crosslink cd23 on b lymphocytes but do not sensitize mast cells |
| CN107074933B (zh) * | 2014-10-24 | 2021-03-19 | 豪夫迈·罗氏有限公司 | 基于vh-vl域间角的抗体人源化 |
| CN107206073A (zh) | 2014-11-14 | 2017-09-26 | 赛诺菲生物技术公司 | 通过施用il‑4r拮抗剂用于治疗伴随鼻息肉的慢性鼻窦炎的方法 |
| MA46098A (fr) | 2016-09-01 | 2019-07-10 | Regeneron Pharma | Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r |
| US10485844B2 (en) | 2016-09-22 | 2019-11-26 | Regeneron Pharmaceuticals, Inc. | Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor |
| TWI784988B (zh) | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| JP2020503316A (ja) | 2016-12-22 | 2020-01-30 | ジェネンテック， インコーポレイテッド | 凍結乾燥ポリペプチドの再構成時間を低減するための方法及び製剤 |
| WO2018129248A1 (en) | 2017-01-06 | 2018-07-12 | The Regents Of The University Of California | Therapeutic anti-ige antibodies and methods and compositions thereof |
| WO2019028367A1 (en) | 2017-08-04 | 2019-02-07 | Regeneron Pharmaceuticals, Inc. | METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES |
| CA3079946A1 (en) | 2017-10-30 | 2019-05-09 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4r antagonist |
| SG11202007564VA (en) | 2018-02-09 | 2020-09-29 | Genentech Inc | Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases |
| CN112203724A (zh) | 2018-03-26 | 2021-01-08 | 诺华股份有限公司 | 使用利格珠单抗治疗慢性自发性荨麻疹的方法 |
| EP3793597A1 (en) | 2018-05-13 | 2021-03-24 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r inhibitor |
| CN109651510B (zh) * | 2018-12-04 | 2023-03-24 | 上海长征医院 | 抗Eno1抗体及其用途 |
| AU2020240132A1 (en) | 2019-03-21 | 2021-09-16 | Regeneron Pharmaceuticals, Inc. | Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy |
| GB2589049C (en) | 2019-04-11 | 2024-02-21 | argenx BV | Anti-IgE antibodies |
| CA3147068A1 (en) | 2019-08-05 | 2021-02-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist |
| JP2021141861A (ja) * | 2020-03-13 | 2021-09-24 | 富士フイルム和光純薬株式会社 | 抗原に対する親和力が向上した抗体のスクリーニング方法および製造方法 |
| WO2021255621A1 (en) | 2020-06-15 | 2021-12-23 | Novartis Ag | Treatment of food allergy using anti-ige antibodies |
| EP4355362A1 (en) | 2021-06-14 | 2024-04-24 | Novartis AG | Pharmaceutical formulation containing an anti-ige antibody |
| WO2023111811A1 (en) | 2021-12-14 | 2023-06-22 | Novartis Ag | Treatment of allergic reactions using anti-ige antibodies |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1268176A (en) * | 1916-11-29 | 1918-06-04 | Us Slicing Machine Co | Power mechanism for slicing-machines. |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5428133A (en) * | 1987-12-31 | 1995-06-27 | Tanox Biosystems, Inc. | Chimeric anti-human IgE-monoclonal antibody which binds to secreted IgE and membrane-bound IgE expressed by IgE-expressing B cells but notto IgE bound to FC receptors on basophils |
| US5449760A (en) | 1987-12-31 | 1995-09-12 | Tanox Biosystems, Inc. | Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils |
| US5614611A (en) * | 1987-12-31 | 1997-03-25 | Tanox Biosystems, Inc. | Humanized monoclonal antibodies binding to IgE-bearing B cells but not basophils |
| DE122006000007I1 (de) | 1987-12-31 | 2006-04-27 | Tanox Biosystems Inc | Antigene epitope, die sich ausschlisslich auf ige-tragenden B-Lymphocyten befinden. |
| US5091313A (en) * | 1988-08-05 | 1992-02-25 | Tanox Biosystems, Inc. | Antigenic epitopes of IgE present on B cell but not basophil surface |
| US6048728A (en) | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| IL94611A (en) | 1989-06-05 | 1994-12-29 | Organogenesis Inc | Medium for cell cultures containing insulin or growth factor similar to insulin, transferrin or iron ion, triiodothyronine or thyroxine and method of use |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| ES2113940T3 (es) * | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
| WO1992017207A1 (en) * | 1991-03-26 | 1992-10-15 | Tanox Biosystems, Inc. | MONOCLONAL ANTIBODIES WHICH BIND TO SECRETED AND MEMBRANE-BOUND IgE, BUT NOT TO IgE ON BASOPHILS |
| AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
| MX9305070A (es) | 1992-08-21 | 1994-04-29 | Genentech Inc | Compocicion farmaceutica que contiene un antagonista de lfa-1 para el tratamiento de transtornos o desordenes mediados por el lfa-1 |
| DE69333484T2 (de) * | 1992-09-24 | 2005-03-24 | Novartis Ag | Umgestaltete monoklonale Antikörper gegen ein Immunglobulinisotyp |
| US5958708A (en) * | 1992-09-25 | 1999-09-28 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
| US6066718A (en) * | 1992-09-25 | 2000-05-23 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
| CA2149329C (en) | 1992-11-13 | 2008-07-15 | Darrell R. Anderson | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
| US6172213B1 (en) * | 1997-07-02 | 2001-01-09 | Genentech, Inc. | Anti-IgE antibodies and method of improving polypeptides |
| US5994511A (en) * | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
| AU2103699A (en) * | 1998-01-29 | 1999-08-16 | Tse Wen Chang | Treating atopic dermatitis with ige antagonists |
| US6299875B1 (en) | 1998-06-04 | 2001-10-09 | Panacea Pharmaceuticals, Llc | Methods to block IGE binding to cell surface receptors of mast cells |
| US20060234296A1 (en) * | 2003-02-01 | 2006-10-19 | Sanjaya Singh | Method for generating high affinity antibodies |
| US20050169909A1 (en) * | 2004-02-02 | 2005-08-04 | Sanjaya Singh | Identification of novel IgE epitopes |
| ES2566778T3 (es) * | 2003-02-01 | 2016-04-15 | Tanox, Inc. | Anticuerpos anti-IgE de humano de alta afinidad |
-
2004
- 2004-02-02 ES ES11170255.1T patent/ES2566778T3/es not_active Expired - Lifetime
- 2004-02-02 DK DK11170255.1T patent/DK2407485T3/en active
- 2004-02-02 EP EP04707368A patent/EP1592776A4/en not_active Withdrawn
- 2004-02-02 AU AU2004209637A patent/AU2004209637A1/en not_active Abandoned
- 2004-02-02 EP EP04707380A patent/EP1592777A4/en not_active Withdrawn
- 2004-02-02 EP EP08104978.5A patent/EP2000481B1/en not_active Expired - Lifetime
- 2004-02-02 ES ES08104978.5T patent/ES2575547T3/es not_active Expired - Lifetime
- 2004-02-02 DK DK08104978.5T patent/DK2000481T3/en active
- 2004-02-02 CN CNA2004800082701A patent/CN1829806A/zh active Pending
- 2004-02-02 CA CA2514840A patent/CA2514840C/en not_active Expired - Lifetime
- 2004-02-02 SI SI200432324A patent/SI2000481T1/sl unknown
- 2004-02-02 CN CN201210316908.4A patent/CN102993306B/zh not_active Expired - Lifetime
- 2004-02-02 US US10/544,056 patent/US7531169B2/en not_active Expired - Lifetime
- 2004-02-02 CN CN2004800070117A patent/CN1771338B/zh not_active Expired - Lifetime
- 2004-02-02 JP JP2006503245A patent/JP4764334B2/ja not_active Expired - Lifetime
- 2004-02-02 CA CA002514839A patent/CA2514839A1/en not_active Abandoned
- 2004-02-02 WO PCT/US2004/002892 patent/WO2004070010A2/en active Application Filing
- 2004-02-02 AU AU2004209638A patent/AU2004209638B2/en not_active Expired
- 2004-02-02 HU HUE11170255A patent/HUE028458T2/en unknown
- 2004-02-02 HU HUE08104978A patent/HUE028407T2/hu unknown
- 2004-02-02 JP JP2006503243A patent/JP2006516408A/ja active Pending
- 2004-02-02 EP EP11170255.1A patent/EP2407485B1/en not_active Expired - Lifetime
- 2004-02-02 PT PT08104978T patent/PT2000481E/pt unknown
- 2004-02-02 WO PCT/US2004/002894 patent/WO2004070011A2/en active Application Filing
- 2004-02-02 SI SI200432311A patent/SI2407485T1/sl unknown
- 2004-07-29 MX MX2011007343A patent/MX338940B/es unknown
-
2006
- 2006-07-17 HK HK06107957.0A patent/HK1085771A1/xx not_active IP Right Cessation
- 2006-07-18 IL IL176940A patent/IL176940A/en active IP Right Grant
-
2009
- 2009-03-27 US US12/413,014 patent/US8252284B2/en active Active
- 2009-06-01 HK HK09104910.0A patent/HK1126788A1/zh not_active IP Right Cessation
-
2010
- 2010-09-09 JP JP2010202452A patent/JP2011042654A/ja active Pending
-
2011
- 2011-04-26 JP JP2011098737A patent/JP5296138B2/ja not_active Expired - Lifetime
- 2011-05-03 AU AU2011202021A patent/AU2011202021B2/en not_active Expired
-
2012
- 2012-07-17 HK HK12106994.9A patent/HK1166330A1/zh not_active IP Right Cessation
- 2012-07-27 US US13/559,938 patent/US8604171B2/en not_active Expired - Lifetime
-
2013
- 2013-11-07 US US14/074,309 patent/US9156908B2/en active Active
-
2016
- 2016-04-04 CY CY20161100269T patent/CY1118063T1/el unknown
- 2016-06-09 CY CY20161100504T patent/CY1117617T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX338940B (es) | Identificacion de epitopos ige novedosos. | |
| CY1120249T1 (el) | Αντισωμα ανταγωνιστης κατευθυνομενο εναντι πεπτιδιου σχετιζομενου με το γονιδιο καλσιτονινης | |
| EA200801735A1 (ru) | Антиамилоидные иммуногенные композиции, способы и применения | |
| EA200800812A1 (ru) | Композиции антитела против cd3 | |
| EA200701305A1 (ru) | Иммуногенные композиции, содержащие циклические пептиды, полученные из бета-амилоидного пептида | |
| CY1116632T1 (el) | Εξουδετερωτες αντισωματων του τελεστη διεγερσης αποικιων κοκκιοκυτταρων μακροφαγων ανθρωπου | |
| EA201000207A1 (ru) | Новые иммуногенные эпитопы для иммунотерапии | |
| EA200700136A1 (ru) | Анти-cd154-антитела | |
| DK1694706T3 (da) | Modificeret anti-CD52-antistof | |
| TR201901841T4 (tr) | Her antikorlarının sabit dozlaması. | |
| MX2018015933A (es) | Epitopes de celulas t reguladoras, composiciones y usos para los mismos. | |
| TW200510459A (en) | RG1 antibodies and uses thereof | |
| MY163480A (en) | Sclerostin binding agents | |
| WO2006009920A3 (en) | Epitope analogs | |
| BRPI0314814C1 (pt) | anticorpo compreendendo uma variante de fc | |
| EA201070812A1 (ru) | Лечение и профилактика амилоидоза | |
| EA200600390A1 (ru) | Химерные антигены для нарушения толерантности хозяина к чужеродным антигенам | |
| EA201070539A1 (ru) | НОВЫЕ АНТИТЕЛА, СПЕЦИФИЧНЫЕ К β-АМИЛОИДНЫМ ПЕПТИДАМ, И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ДИАГНОСТИЧЕСКИХ ИЛИ ЛЕКАРСТВЕННЫХ СРЕДСТВ | |
| EA201100070A1 (ru) | Туберкулезный белок rv2386c, композиции и их применения | |
| WO2008098917A3 (en) | Novel antibodies against igf-ir | |
| EP2542571A4 (en) | OLIGOMER SPECIFIC BETA AMYLOID EPITOPE AND ANTIBODIES | |
| UA94211C2 (ru) | Выделенное полностью человеческое моноклональное cd3 антитело | |
| EA201100071A1 (ru) | Новые композиции и способы | |
| EA200800601A1 (ru) | Связывающие fas антитела | |
| ATE401344T1 (de) | T-zellen-epitope in erythropoietin |